he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
- 2022-05-03癫痫患者在肉类方法有哪些注意事项
- 2022-05-02儿童癫痫的发病主因有哪些
- 2022-04-252013年国际抗癫痫联合会抗癫痫药剂使用指南
- 2022-04-13癫痫猝死:凶手是谁?
- 2022-04-12心理百科:春节期间小心疾病
- 2022-04-11抗癫痫药物预防新发癫痫:任重而道远
- 癫痫猝死:凶手是谁?
- 心理百科:春节期间小心疾病
- 抗癫痫药物预防新发癫痫:任重而道远
- 银屑病药物 Brodalumab 自杀倾向副作用AZ 遭受重创
- 诺华银屑病药物 Secukinumab 比依那西普好
- 癫痫治疗障碍仍难以克服
- 中华医学会系列精选指南|急性腹痛、淋巴瘤、银屑病的诊断和治疗
- 长期吃黑芝麻的人能治好白发吗?
- 银屑病常用药物进入医疗保险,有效减轻患者的医疗负担
- 生发偏方 4种生发偏方使头发更浓密
- 白癜风症状 有些白斑可以预防白癜风
- 广西百色破获药案:涉及74家药店,3000多盒
- 特发性癫痫大发作药物治疗的首选
- 孩子脸上有白斑,肚子里有蛔虫?医生:不是蛔虫斑,可能是癌症
- 血清钙水平可预测甲氨蝶呤治疗银屑病的效果
- 如何最有效地去除黑头?
- 揭露手指月牙的东西 拇指经常有小指(8)
- 孩子的症状是什么?
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 胰高血糖素瘤 胰高血糖素瘤的临床表现是什么?
- 如何预防疾病?
- 治疗皮肤病的女性远离各种皮肤病
- 白癜风患者的饮食调理
- 箕星宣布aficamten在中国获得突破性治疗药物认定
- 如何预防儿童白癜风?
- 试验性依那西普生物类似物 CHS-0214 3 期研究的主要终点
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- 癫痫病的类似症状是什么样
- 女性癫痫病的怎么放射治疗
- 罕有病例:自发性颞极膨出伴癫痫发作
- 癫痫病的性疾病有哪些
- 第五届 CAAE 国际癫痫年会
- 癫痫病的早于症状是什么样的
- 癫痫病人能治好吗 癫痫病的放射治疗方法
- 外科手术癫痫病比较好的药
- 癫痫病发作常因哪些症状
- 【用药问答】控制癫痫患者再抽搐, 可配上的药物不包括?
- 癫痫病的高血压有哪些呢
- 有系统癫痫的先兆研究
- 癫痫病发病其实是怎么回事